Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Inclusion Criteria: * Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * Patients must meet the following laboratory criteria (unless dysfunction is due to organ infiltration by lymphoma): * ANC ≥ 1.5 x 10\^9/L * Hemoglobin ≥ 9 g/dl * Platelets ≥ 75 x 10\^9/L * Calculated CrCl ≥50 mL/min (MDRD Formula) * Total serum calcium ≥ LLN * Total serum magnesium ≥ LLN * Aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN * Serum bilirubin ≤1.5 x ULN * Serum potassium ≥ LLN * Thyroid stimulating hormone (TSH) ≥ lower limit of normal (LLN) and free T4 within normal limits. Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism. * Baseline multiple uptake gate acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional normal. * Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 * Documented MCL by biopsy or CLL by biopsy or flow cytometry. * Relapsed or refractory disease despite 1 or more lines of therapy. Exclusion Criteria: * Prior histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer * Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment * Peripheral neuropathy ≥ Common Terminology Criteria for Advers…